Evidence map›Paper›PMID 26062108›Full record

Trial reportGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology2015

Treatment of menopausal symptoms with three low-dose continuous sequential 17β-estradiol/progesterone parenteral monthly formulations using novel non-polymeric microsphere technology.

Manuel Cortés-Bonilla, Roberto Bernardo-Escudero, Rosalba Alonso-Campero, María T Francisco-Doce, Marcelino Hernández-Valencia, Cuauhtémoc Celis-González, Ricardo Márquez-Oñate, Peter Chedraui, Juan A Uribe

Open access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Variation in menopausal vasomotor symptoms outcomes in clinical trials: a systematic review.BJOG : an international journal of obstetrics and gynaecology · 2020
    Pooled it
  2. Bioidentical hormones for women with vasomotor symptoms.The Cochrane database of systematic reviews · 2016
    Pooled it
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Manuel Cortés-Bonillaa Instituto Nacional de Perinatología "Isidro Espinosa de los Reyes" , Mexico City , Mexico .
Roberto Bernardo-Escudero
Rosalba Alonso-Campero
María T Francisco-Doce
Marcelino Hernández-Valencia
Cuauhtémoc Celis-González
Ricardo Márquez-Oñate
Peter Chedraui
Juan A Uribe
Centro de Estudios Tecnológicos y Universitarios · MXMexican Association for the Clinical Research · MXMexican Social Security Institute · MXUniversisdad Católica de Santiago de Guayaquil · EC

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo analyze the short-term efficacy and safety over menopausal symptoms of three low-dose continuous sequential 17β-estradiol (E)/progesterone (P) parental monthly formulations using novel non-polymeric microspheres.

methodsThis was a multicenter, randomized, single blinded study in which peri- and postmenopausal women were assigned to receive a monthly intramuscular injection of 0.5 mg E + 15 mg P (Group A, n = 34), 1 mg E + 20 mg P (Group B, n = 24) or 1 mg E + 30 mg P (Group C, n = 26) for 6 months. Primary efficacy endpoints included mean change in the frequency and severity of hot flushes and the effect over urogenital atrophy symptoms at 3 and 6 months. Safety variables included changes in the rate of amenorrhea, endometrial thickness and histopathology, and local and systemic adverse events.

resultsCompared to baseline at month 6, the three treatment schemes significantly decreased the rate of urogenital atrophy symptoms and the frequency (mean number per day) and severity (mean number graded as moderate and severe per month) of hot flushes. No differences in studied efficacy parameters were observed between studied groups at baseline or at the end of the study. For all groups the most frequent adverse event was pain at the injection site; however they were all rated as mild. At the end of the study peri- and postmenopausal women displayed no significant changes in endometrial thickness or histopathology in all treated groups. The rate of amenorrhea at the end of the study decreased for all studied groups yet was less evident among postmenopausal women as compared to perimenopausal ones.

conclusionsThe three low-dose continuous sequential intramuscular monthly treatments of E/P using novel microsphere technology were effective at reducing menopausal symptoms at short-term with a low rate of adverse events. More long-term and comparative research is warranted to support our positive findings.

Indexed as

MenopauseAdultAtrophyEstradiolEstrogen Replacement TherapyFemaleFemale Urogenital DiseasesHormone Replacement TherapyHot FlashesHumansInjections, IntramuscularMicrospheresMiddle AgedProgesteroneSingle-Blind MethodTreatment OutcomeEstradiolProgesteroneHormonal therapyinjectable estradiolmenopausemicrospheresprogesteronevasomotor symptoms

Identifiers

PMID26062108
PMCPMC4776687
OpenAlexW1661651846

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.